SciELO - Scientific Electronic Library Online

 
vol.64 número3Is serum angiotensin converting enzyme level a useful non-invasive marker for liver fibrosis in patients with chronic hepatitis C?Qualidade de vida em uma amostra de adultos brasileiros utilizando o questionário genérico SF-12 índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

Compartilhar


Revista da Associação Médica Brasileira

versão impressa ISSN 0104-4230versão On-line ISSN 1806-9282

Resumo

WANG, Zhen; ZHENG, Yisheng  e  FANG, Zhenjian. The clinical efficacy and safety of paclitaxel combined with avastin for NSCLC patients diagnosed with malignant pleural effusion. Rev. Assoc. Med. Bras. [online]. 2018, vol.64, n.3, pp.230-233. ISSN 1806-9282.  https://doi.org/10.1590/1806-9282.64.03.230.

Objective:

The current study aimed to investigate the clinical efficacy of paclitaxel combined with avastin for non-small cell lung cancer (NSCLC) patients diagnosed with malignant pleural effusion (MPE).

Method:

Total of 33 patients diagnosed with NSCLC as well as malignant pleural effusion were included. All of them received paclitaxel (175 mg/m2) and avastin (5 mg/kg). Clinical efficacy was evaluated using the total response rate, overall survival, progression-free survival and changes in MPE volume. Adverse events and rates of toxicities were examined as well.

Results:

The total response rate reached 77% while the overall survival and the median progression-free survival were respectively 22.2 months and 8.4 months. Toxicities of grade 3-4 consisted of neutropenia in 57% of patients, anemia in 17% of them, febrile neutropenia in 11%, as well as anorexia in 7%. No treatment-correlated deaths were found.

Conclusion:

Paclitaxel combined with avastin decreased MPE volume and increased survival rate of NSCLC patients via inhibiting vascular endothelial growth factor expression.

Palavras-chave : Carcinoma, Non-Small-Cell Lung; Pleural Effusion, Malignant; Paclitaxel; Bevacizumab; Vascular Endothelial Growth Factor A.

        · texto em Inglês     · Inglês ( pdf )